Log in

NASDAQ:NERVMinerva Neurosciences Stock Price, Forecast & News

$3.92
-0.34 (-7.98 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.91
Now: $3.92
$4.40
50-Day Range
$3.71
MA: $9.61
$14.70
52-Week Range
$1.81
Now: $3.92
$15.22
Volume8.88 million shs
Average Volume7.22 million shs
Market Capitalization$153.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIb clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company' preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, NV for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Read More
Minerva Neurosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NERV
CUSIPN/A
Phone617-600-7373

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.71 per share

Profitability

Net Income$-72,180,000.00

Miscellaneous

Employees13
Market Cap$153.74 million
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive NERV News and Ratings via Email

Sign-up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions

How has Minerva Neurosciences' stock been impacted by COVID-19 (Coronavirus)?

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NERV shares have decreased by 38.4% and is now trading at $3.92. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Minerva Neurosciences?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Minerva Neurosciences.

When is Minerva Neurosciences' next earnings date?

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Minerva Neurosciences.

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences Inc (NASDAQ:NERV) posted its earnings results on Monday, May, 4th. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.05. View Minerva Neurosciences' earnings history.

What price target have analysts set for NERV?

6 Wall Street analysts have issued twelve-month price objectives for Minerva Neurosciences' stock. Their forecasts range from $2.00 to $26.00. On average, they expect Minerva Neurosciences' share price to reach $14.83 in the next twelve months. This suggests a possible upside of 278.4% from the stock's current price. View analysts' price targets for Minerva Neurosciences.

Has Minerva Neurosciences been receiving favorable news coverage?

News headlines about NERV stock have trended negative this week, according to InfoTrie. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Minerva Neurosciences earned a media sentiment score of -2.7 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutMinerva Neurosciences.

Are investors shorting Minerva Neurosciences?

Minerva Neurosciences saw a decrease in short interest in May. As of May 15th, there was short interest totaling 2,820,000 shares, a decrease of 5.4% from the April 30th total of 2,980,000 shares. Based on an average trading volume of 392,500 shares, the short-interest ratio is presently 7.2 days. Approximately 9.0% of the shares of the company are sold short. View Minerva Neurosciences' Current Options Chain.

Who are some of Minerva Neurosciences' key competitors?

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include PTC Therapeutics (PTCT), Inovio Pharmaceuticals (INO), Immunomedics (IMMU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), ImmunoGen (IMGN), VBI Vaccines (VBIV), Exelixis (EXEL), TG Therapeutics (TGTX) and Cara Therapeutics (CARA).

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the following people:
  • Dr. Rémy Luthringer, Exec. Chairman & CEO (Age 58)
  • Mr. Geoffrey Robin Race, Exec. VP, CFO, Chief Bus. Officer & Company Sec. (Age 58)
  • Dr. Michael Davidson, Chief Medical Officer (Age 69)
  • Mr. Richard Russell, Pres (Age 55)
  • Mr. Joseph Reilly, Sr. VP & COO (Age 44)

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Who are Minerva Neurosciences' major shareholders?

Minerva Neurosciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.33%), State Street Corp (1.31%), Geode Capital Management LLC (1.25%), Nuveen Asset Management LLC (1.03%), Acadian Asset Management LLC (0.48%) and Sphera Funds Management LTD. (0.43%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, Richard E Russell, Venture Associates L Index III and William F Doyle. View institutional ownership trends for Minerva Neurosciences.

Which institutional investors are selling Minerva Neurosciences stock?

NERV stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., JPMorgan Chase & Co., Squarepoint Ops LLC, State Street Corp, GSA Capital Partners LLP, Connor Clark & Lunn Investment Management Ltd., Morgan Stanley, and BlackRock Inc.. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, and Venture Associates L Index III. View insider buying and selling activity for Minerva Neurosciences.

Which institutional investors are buying Minerva Neurosciences stock?

NERV stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Deutsche Bank AG, Russell Investments Group Ltd., Acadian Asset Management LLC, AQR Capital Management LLC, Geode Capital Management LLC, Two Sigma Advisers LP, and Trexquant Investment LP. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer, and William F Doyle. View insider buying and selling activity for Minerva Neurosciences.

How do I buy shares of Minerva Neurosciences?

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $3.92.

How big of a company is Minerva Neurosciences?

Minerva Neurosciences has a market capitalization of $153.74 million. The biopharmaceutical company earns $-72,180,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe.

What is Minerva Neurosciences' official website?

The official website for Minerva Neurosciences is www.minervaneurosciences.com.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.